<DOC>
	<DOCNO>NCT01196143</DOCNO>
	<brief_summary>This phase IV non-interventional , multicentric observational study evaluate baseline follicle stimulate hormone ( FSH ) level , ovarian volume , antral follicle count ( AFC ) age prognostic factor outcome in-vitro fertilisation/intracytosolic sperm injection ( IVF/ICSI ) infertile subject receive Gonal-f control ovarian hyperstimulation ( COH ) .</brief_summary>
	<brief_title>A Study Evaluate Baseline Follicle Stimulating Hormone , Ovarian Volume Antral Follicle Count Prognostic Factors Outcome In-vitro Fertilisation/Intracytosolic Sperm Injection Infertile Patients Receiving Gonal f Controlled Ovarian Hyperstimulation</brief_title>
	<detailed_description>Treatment subfertility infertility assist reproduction technology ( ART ) IVF embryo transfer ( ET ) require multiple follicular development increase number female gamete , chance successful treatment outcome . These technology include stimulation multiple follicular development exogenous FSH administration suppression endogenous luteinizing hormone ( LH ) secretion administration GnRH analogue ( antagonist agonist , require ) . A single dose human chorionic gonadotropin ( hCG ) administer mimic endogenous LH surge induce final oocyte maturation adequate follicular development . Recombinant-hFSH ( r-hFSH ) show efficacious term number oocyte recover term pregnancy rate compare urinary-hFSH . Gonal-f fill-by-mass available liquid formulation administer pen device . The pen device prefilled hence subject require assemble device make simple use . The prefilled pen allow accurate delivery precise dose r-hFSH 37.5 International Units ( IU ) increment . OBJECTIVES Primary objective : - Evaluation significance baseline FSH , ovarian volume AFC model adjust age prognostic factor IVF/ICSI treatment outcome . This study plan enrol 500 female subject undergo COH IVF/ICSI-treatment Gonal-f. Gonal-f administer daily subcutaneously ( s.c. ) accord centre 's usual clinical practice , commence Days 2 3 cycle stimulation period . Treatment Gonal-f continued adequate follicular development achieve dose adjust accord subject 's response , usually high 450 IU daily . A single injection 250 microgram r-hCG 5,000 IU 10,000 IU hCG would administer 24-48 hour last Gonal-f injection induce final follicular maturation . Gonal-f start approximately 2 week start gonadotrophin-releasing hormone ( GnRH ) agonist treatment , continue adequate follicular development achieve . Oocyte retrieval do 34-36 hour hCG administration follow IVF/ICSI treatment accord clinic 's protocol . Each enrol subject would follow confirmation pregnancy status . Active follow pregnancy perform , include subject withdrawn study .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Premenopausal female subject age 2043 year Subjects require treatment recombinant FSH COH IVF and/or ICSI Subjects able communicate well investigator comply requirement entire study Subjects give write informed consent , prior treatment , understanding consent may withdraw subject time without prejudice Female subject pregnant lactating Subjects know allergic reaction one ingredients Subjects enlarge ovary cyst unrelated polycystic ovarian disease . Subjects gynaecological bleed unknown origin Subjects ovarian , uterine , mammary cancer Subjects hyperprolactinaemia Subjects tumor hypothalamus pituitary gland</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Ovulation induction</keyword>
	<keyword>Intrauterine insemination</keyword>
	<keyword>Gonal-f</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Female infertility</keyword>
</DOC>